A Phase IIB Clinical Trial of Normobaric Oxygen Therapy (NBO) in Acute Ischemic Stroke (AIS) (S02.001)
CONCLUSIONS: NBO did not affect NIHSS or infarct growth in this trial. The observed imbalance in deaths remains unexplained, but appears unrelated to NBO. Further studies are warranted.Supported by: NIH-NINDS.Disclosure: Dr. Singhal has received personal compensation as an expert witness in medicolegal cases involving stroke in young adults. Dr. Singhal's wife is an employee of Vertex Pharmaceuticals, Inc. Dr. Singhal has received research support from Pfizer and Photothera, Inc. Dr. On Behalf of Partners SPOTRIAS Investigators has nothing to disclose.
Source: Neurology - Category: Neurology Authors: Singhal, A., on Behalf of Partners SPOTRIAS Investigators, Tags: S02 Acute Stroke Therapy Source Type: research
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Cancer in Young Adults | Chronic Obstructive Pulmonary | Clinical Trials | Hemorrhagic Stroke | Ischemic Stroke | Neurology | Pfizer | Stroke | Study | Women